PM226
PM226 is a selective cannabinoid CB2R agonist (Ki (CB2R)=13 nM; EC50 (CB2R)=39 nM; Ki (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo.
For research use only. We do not sell to patients.
- CAS No.: 1949726-13-9
- Formula: C22H31NO3
- Molecular Weight:357.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-15443
AM251CB1 Receptor Antagonist -
HY-110004
ACEABiochemical Assay Reagent -
HY-13439
SR144528CB2 Receptor Antagonist -
HY-10013
TaranabantCB1 Receptor Invert Agonist -
HY-18697
JD-5037CB1 Receptor Antagonist -
HY-10871
OtenabantCannabinoid Receptor Antagonist -
HY-13505
AM281CB1 Antagonist -
HY-116649
CB1 antagonist 2CB1R Antagonist -
HY-14167
GW842166XCannabinoid Receptor Agonist -
HY-13288
Org 27569Cannabinoid Receptor Modulator -
HY-110206
AM6545CB1 Receptor Antagonist -
HY-117139
NESS 0327Cannabinoid Antagonist
Biological Activity
Description
IC50 & Target
[1]|
CB2 13 nM (Ki) |
CB2 39 nM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
38.6 nM
Compound: 43
|
Agonist activity at human CB2 receptor expressed in HEK293 cell membranes assessed as induction of [35S]-GTPgammaS binding after 60 mins by liquid scintillation spectrometric method
Agonist activity at human CB2 receptor expressed in HEK293 cell membranes assessed as induction of [35S]-GTPgammaS binding after 60 mins by liquid scintillation spectrometric method
|
[PMID: 27309150] |
| HEK293 | IC50 |
4.2 nM
Compound: 43
|
Agonist activity at human CB2 receptor expressed in HEK293 cell membranes assessed as inhibition of forskolin-stimulated cAMP accumulation after 60 mins by HTRF assay
Agonist activity at human CB2 receptor expressed in HEK293 cell membranes assessed as inhibition of forskolin-stimulated cAMP accumulation after 60 mins by HTRF assay
|
[PMID: 27309150] |
In Vitro
PM226 binds selectively to CB2 receptor with an affinity in the nanomolar range (Ki=12.8±2.4 nM). PM226 has negligible affinity for the CB1 receptor (Ki >40000 nM) and no activity at the GPR55. PM226 was also evaluated in GTPγS binding assays specific to the CB2 receptor showing agonist activity (EC50=38.67±6.70 nM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Malonate-lesioned adult (12 week old; 350-400 g) male Wistar rats[2]
-
Dosage:0.1, 1 and 10 mg/kg
-
Administration:Administered i.p.
-
Result:Reduced the volume of edema observed in Malonate-lesioned rats at the dose of 1 mg/kg.
Chemical Information
-
CAS No. 1949726-13-9
-
Molecular Weight 357.49
-
Formula C22H31NO3
-
SMILES
CC1(C)OC2=CC(C(C)(C)CCCCCC)=CC(OC)=C2C3=C1C=NO3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Gemma Navarro, et al. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Front Neurosci. 2016 Sep 13;10:406. [Content Brief]
[2]. M Gómez-Cañas, et al. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-215. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PM226 Related Classifications
HY-136238 Related Classifications
Powered by Bioz